Objects
Huober, J., Cole, B. F., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I.. Springer; 2014. Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Bernhard, J., Zahrieh, D., Green, M. D., Colleoni, M., Gelber, R. D., Castiglione-Gertsch, M., Price, K. N., Goldhirsch, A., Coates, A. S., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., Forbes, J. F., Aebi, S., Yeo, W., Thurlimann, B.. Nature Publishing Group; 2008. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.
Viale, G., Regan, M. M., Lang, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M.. Oxford University Press; 2011. Which patients benefit most from adjuvant aromatase inhibitors?: results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Regan, M. M., Walley, B. A., Spazzapan, S., Parmer, V., Ruhstaller, T., Abdi, E. A., Gelber, R. D., Coates, A. S., Goldhirsch, A., Pagani, O., Francis, P. A., Fleming, G. F., Lang, I., Gomez, H. L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M.. Oxford University Press; 2017. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.. Oxford University Press; 2009. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.